>MOGN's MGI 114 vs. OvaRex
Remember that these patients have already been through the wringer and then some - multiple treatment taxol/platinol failures. Thus the drop outs are possibly not all MGI-114's fault. This is a very tough patient population indeed.<
This release from AXO:
OvaRex(TM) Clinical Data Presented at the Society of Gynecologic Oncologists Annual Meeting
-Additional Data Reinforces Emerging Potential of Monoclonal Antibody-
SAN DIEGO, Feb. 8 /CNW/ -- AltaRex Corp. (Toronto: AXO) today
announced the presentation of additional retrospective data of OvaRex(TM) MAb,
for the treatment of advanced stage ovarian cancer, at the 31st Annual Meeting
of the Society of Gynecologic Oncologists in San Diego. The findings are a
result of work conducted by Richard Baum, MD, PhD, Professor of Nuclear
Medicine, University of Frankfurt/Main, Chairman of the Clinic of Nuclear
Medicine / P.E.T. Center Bad Berka, involving Positron Emission Tomograpy (PET
Imaging) on a group of 11 relapsed ovarian cancer patients with advanced
disease who received multiple doses of OvaRex(TM) MAb. Professor Baum
documented disease stabilization or regression of selected lesions using PET
imaging in five of the 11 patients treated with OvaRex(TM) MAb.
"The package of clinical data that is emerging from our studies supports
the potential utility of OvaRex(TM) MAb in the treatment of advanced ovarian
cancer," remarked Christopher Nicodemus, MD, Senior Vice President of Clinical
Research and Development for AltaRex. "We believe the data from this
analysis, while from a small group of patients, demonstrates that
immunotherapy with OvaRex(TM) MAb may be capable of stabilizing and, in some
cases, shrinking tumors. Coupled with updated results from a similar group of
relapsed ovarian cancer patients being treated with OvaRex(TM) MAb in an open-
label phase II study in Vancouver, we believe that the clinical development of
OvaRex(TM) MAb is progressing extremely well."
"The compilation of this data has given the Company the support it needs
to continue its aggressive pursuit of the appropriate corporate partner,"
remarked Richard Bagley, President and CEO of AltaRex. "We believe we have a
very compelling opportunity for a corporate partner with OvaRex(TM) MAb, which
is in late-stage development. This clinical data allows us to move forward
with partnering approaches that differ considerably from our previous efforts
and we believe assists us in structuring a deal that will see OvaRex(TM) reach
its full potential while rewarding shareholders accordingly."
AltaRex Corp. is an antibody-based company focused on the development and
commercialization of unique products for the treatment of late stage cancers.
The Company's proprietary platform technology, Antibody-based ImmunoTherapy,
or AIT(R), is designed to enhance the ability of the human immune system to
produce its own anti-tumor response and allows for a cost-effective and timely
evaluation of preclinical candidates. The Company has identified five product
candidates for clinical evaluation.
Aggressive disease, glad to see promising results.
RWR |
